Guggenheim S&P 500® Eq Weight HC ETF

Analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017.

On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit.

Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).

Bristol-Myers Squibb (BMY) reported a rise of 17% in revenue to ~$19.4 billion in 2016, compared to $16.6 billion in 2015. The company reported a net profit of ~$4.5 million in 2016.

Due to Johnson & Johnson’s wide geographic presence, expansive product portfolio, and strong cash flow, its valuation multiple has witnessed a gradual rise.

Varian Medical Systems (VAR) is a global medical device company that generates ~50% of its total revenues from North America and 26% and 24% of total revenues from Europe and Asia, respectively.

Due to Medtronic’s strong fundamentals, the company’s valuation multiple has witnessed a gradual rise since its 3Q16 earnings release.

On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.

Abbott Laboratories is a global healthcare company that sees 70% of its total revenues generated in markets outside the United States.

Becton, Dickinson and Company (BDX), or BD, has operations across the globe, with more than 50% of its 2015 revenues coming from international markets.

In this article, we’ll compare Dentsply against its peers and the ETFs that invest in Dentsply.